Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center

Frontiers in Neurology
Thomas RouxCaroline Papeix

Abstract

Fingolimod (Fg), a sphingosine 1-phosphate receptor modulator, decreases the annual relapse rate (ARR) in relapsing-remitting multiple sclerosis (RRMS). The aim of this study was to assess the efficacy and safety of Fg in daily practice in patients with RRMS, previously treated with natalizumab (Nz) or not, and systematically followed during at least 1 year. Data were collected from the patient files. Primary endpoint was the comparison between the ARR the year before Fg onset and after 1 and 2 years of Fg treatment. The secondary endpoints were the difference between Expanded Disability Status Scale (EDSS) at Fg onset and after 1 and 2 years of treatment, and safety. In the whole sample, we confirmed Fg efficacy on the ARR (0.895 before vs. 0.364 1 year after, p < 0.0001). Between our two groups (with or without Nz before Fg), the ARR was higher in the Nz group during the first year but similar during the second year. The EDSS was stable during the first year of Fg but significantly higher after 2 years (3.33 vs. 3.72, p = 0.02). Concerning safety, only three patients had to discontinue Fg because of tolerance issues. Our study showed that Fg is safe in RRMS and can be used either after first-line treatments or after Nz. Howev...Continue Reading

References

Aug 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·C ConfavreuxA J Thompson
Nov 12, 2005·Annals of Neurology·Chris H PolmanJerry S Wolinsky
Jan 22, 2010·The New England Journal of Medicine·Ludwig KapposUNKNOWN FREEDOMS Study Group
Jan 22, 2010·The New England Journal of Medicine·Jeffrey A CohenUNKNOWN TRANSFORMS Study Group
Apr 27, 2011·Annals of Neurology·Jeffrey A Cohen, Jerold Chun
Jan 23, 2013·Acta Neurologica Scandinavica·A P SempereE Feliu-Rey
Jul 31, 2013·Nature Reviews. Neurology·Maria Pia Sormani, Nicola De Stefano
Sep 7, 2013·Journal of Neurology·Stefan BrauneUNKNOWN NTC Study Group
Feb 26, 2014·JAMA Neurology·Mikael CohenUNKNOWN Club Francophone de la Sclérose en Plaques Investigators
Mar 13, 2014·Neurology·Vilija G JokubaitisUNKNOWN MSBase Study Group
May 21, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Robert HoepnerIngo Kleiter
Jul 6, 2014·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M CapobiancoA Bertolotto
Sep 27, 2014·Multiple Sclerosis : Clinical and Laboratory Research·G ComiL Kappos
Oct 2, 2014·The International Journal of Neuroscience·Carrie M HershDaniel Ontaneda
May 31, 2015·Neurology·Ludwig KapposUNKNOWN TOFINGO study group
Sep 13, 2015·Brain : a Journal of Neurology·Pietro IaffaldanoUNKNOWN Italian iMed-Web database
Jan 31, 2016·Neurology·Laetitia BarbinUNKNOWN CFSEP and OFSEP groups
Apr 9, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Nils Koch-HenriksenPer Soelberg Sørensen
Nov 16, 2016·Neurology. Neuroimmunology and Neuroinflammation·Caroline PapeixUNKNOWN TYSEDMUS and OFSEP Group

❮ Previous
Next ❯

Citations

Apr 3, 2020·PloS One·Francisco BarreroUNKNOWN in representation of the MS NEXT study investigators
Aug 29, 2017·Expert Opinion on Pharmacotherapy·Katja ThomasTjalf Ziemssen
Aug 11, 2020·Revue neurologique·V PantazouM Théaudin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.